Cryoport, Inc. filed its quarterly report on Form 10-Q with the SEC on November 5, 2026, covering the three and nine months ended September 30, 2026, disclosing continued revenue growth alongside an expanded operating loss compared with the prior-year period.
Key Highlights
- Total revenue of $50.2 million for the three months ended September 30, 2026, up from $44.2 million in the same quarter of 2025, according to the filing.
- Loss from operations of $8.8 million for Q3 2026, compared with a loss of $9.9 million in Q3 2025, the company reported.
- Net loss of $10.9 million for the third quarter of 2026, against a net loss of $6.9 million for Q3 2025, as disclosed in the filing.
- Accumulated deficit of $718.5 million as of September 30, 2026, up from $688.9 million at December 31, 2025.
- Cash and cash equivalents of $279.2 million at September 30, 2026, compared with $250.5 million at December 31, 2025.
- 50,700,429 shares of common stock outstanding as of October 30, 2026, per the filing cover page.
- Current portion of convertible senior notes of $186.0 million, net of a $0.2 million discount, as of September 30, 2026.
Cryoport's Third-Quarter 2026 Financial Results: Revenue Growth, Wider Net Loss
According to the Form 10-Q filed with the SEC, Cryoport, Inc. (NASDAQ:CYRX) reported total revenue of $50,220 thousand for the three months ended September 30, 2026, an increase from $44,233 thousand in the comparable prior-year period. Life sciences services revenue was $28,564 thousand and life sciences products revenue was $21,656 thousand for the quarter. For the nine months ended September 30, 2026, total revenue reached $146,989 thousand, up from $130,727 thousand a year earlier.
The filing disclosed a gross margin of $23,834 thousand for Q3 2026, compared with $21,325 thousand in Q3 2025. Total operating costs and expenses for the quarter were $32,638 thousand, including selling, general and administrative expenses of $27,904 thousand and engineering and development costs of $4,734 thousand, resulting in a loss from operations of $8,804 thousand. For the nine-month period, the loss from operations was $28,457 thousand. Net loss per share on a basic and diluted basis was $0.25 for Q3 2026 and $0.71 for the nine months ended September 30, 2026, the filing stated.
On the balance sheet, the company reported total assets of $750,945 thousand at September 30, 2026, down from $764,989 thousand at December 31, 2025. Total stockholders' equity declined to $483,514 thousand from $502,638 thousand over the same period. The filing also noted that Class C convertible preferred stock, with 200,000 shares issued and outstanding, carried a value of $48,275 thousand, reflecting paid-in-kind dividends of $6,000 thousand recognized through the nine-month period. For the nine months ended September 30, 2025, the company reported net income of $89,945 thousand, which included income from discontinued operations of $115,393 thousand, as disclosed in the comparative income statement.
What Was Disclosed
Cryoport filed its Q3 2026 Form 10-Q reporting total quarterly revenue of $50.2 million, a loss from continuing operations of $10.9 million, cash of $279.2 million, and an accumulated deficit of $718.5 million as of September 30, 2026.



Please wait processing your request...